Document is current

Article History

Received: 5 July 2023

Accepted: 20 October 2023

First Online: 20 December 2023

Declarations

:

: This study has been reviewed and approved by the Thomas Jefferson University IRB (May 24, 2022; 22G.387) in addition to the relevant ethics committees at participating sites in India. An informed consent form has been developed and approved for this study and will be used to obtain informed consent from all participants prior to enrolment in the study.

: The informed consent form used for this study is available from the corresponding author on request.

: The authors disclose the following:<i>•</i> Richard Derman currently receives research funding from the Children’s Investment Fund Foundation (CIFF), the National Institutes of Health (NIH), the Foundation for the National Institutes of Health (FNIH), the Bill & Melinda Gates Foundation (BMGF), and the Thrasher Research Fund.<i>•</i> Michael Auerbach receives grant funding from Pharmacosmos and Covis and has received payment for educational, non-promotional programs on the use of IV iron from Pharmacosmos, Pfizer, and American Regent.<i>•</i> Rupsa Boelig receives grant funding from Covis, NIH, March of Dimes, Thrasher Research Fund, and Pharmacosmos.<i>•</i> Michael Georgieff receives grant funding from NIH, CIFF, and BMGF.<i>•</i> Mrutyunjaya B. Bellad received 100 doses each of ferric carboxymaltose (FCM) and ferric derisomaltose (FDM) from the local distributors (Emcure and Lupin respectively) free of cost for thesis (postgraduate research study) work of one of the OBGYN Residents.<i>•</i> Benjamin Leiby receives grant funding from CIFF, NIH, BMGF, and GlaxoSmithKline, and serves on a DSMB for Alpha Tau Medical.